Collaborative approach may speed discovery of brand-new preventive treatments for Alzheimer’s disease The future success of Alzheimer's prevention study could rely on the power of researchers from different clinical trials to build collaborative relationships that facilitate the posting of information, resources and expertise that may rate the discovery of new preventive treatments, according to leading Alzheimer's researchers who published a Perspectives article, ‘CAP–advancing the evaluation of preclinical Alzheimer disease remedies,today in Nature Evaluations Neurology ‘ online. The 12 co-authors, representing six scientific trials and two organizations keenly thinking about Alzheimer's, are section of the Collaboration for Alzheimer's Avoidance , formed in 2011 to greatly help researchers learn from and support each other's work; talk about data; harmonize data trial and gathering outcomes to permit for comparability across research; hold open up, informal dialogue with regulators; and chart fresh territories.

Collaborative pharmaceutical project concentrating on paediatric formulation development gets go-ahead A collaborative pharmaceutical project centered on improving the pathway for developing paediatric formulations has been given the go-ahead after successfully securing an technology grant. The consortium is made up of pharmaceutical analytical advancement expert Molecular Profiles along with Pfizer, Bristol Myers Squibb, GlaxoSmithKline and academic establishments including University College London, University of Bath, University of Birmingham, Aston University and the Academy of Pharmaceutical Sciences . Paediatric formulation development is more complex than the associated adult medicines. In addition to considering the variations in physiology and anatomy, paediatric formulations must present flexible dosing and provide effective taste-masking.